Akums Q1 FY27 Revenue Surges 13.9% YoY to ₹1,167 Crore, PAT Jumps to ₹101 Crore
Akums Drugs and Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹1,167 crore, up 13.9% YoY. EBITDA increased 35.4% to ₹175 crore, and PAT rose to ₹101 crore from ₹65 crore. The CDMO business grew significantly, with revenue reaching ₹964 crore. Management expressed confidence in sustainable growth.
The substantial growth in key financial metrics and the positive outlook provided by the management are likely to have a significant positive impact on investor sentiment and the company's stock performance.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with improved margins, indicating strong financial performance.
Akums Drugs and Pharmaceuticals Ltd. announced its consolidated financial results for the quarter ended June 30, 2026, reporting a strong start to FY27. The company achieved an operating revenue of ₹1,167 crore, a 13.9% increase year-on-year from ₹1,024 crore in Q1 FY26. EBITDA grew by 35.4% to ₹175 crore, with the EBITDA margin improving to 15.0% from 12.6% in the previous year. Profit After Tax (PAT) stood at ₹101 crore, a significant rise from ₹65 crore in the corresponding quarter of FY26, with PAT margin improving to 8.4% from 6.2%. The Contract Development and Manufacturing Organization (CDMO) business was the primary growth driver, with CDMO revenue increasing to ₹964 crore from ₹813 crore in Q1 FY26. CDMO EBITDA saw a 36.8% year-on-year growth to ₹163 crore from ₹119 crore in Q1 FY26. Mr. Sanjeev Jain, Managing Director, commented that FY27 has begun on a strong and encouraging note, highlighting the consistent performance of the CDMO business and the trust clients place in Akums. Mr. Sandeep Jain, Managing Director, added that the company remains focused on strengthening its CDMO leadership, scaling high-value capabilities, and driving operational excellence, positioning Akums for sustainable growth.
What to do with a filing like this
Akums Drugs and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Akums Drugs and Pharmaceuticals Limited. Read the original for the full detail.